Business
Telix (ASX:TLX) share price slips despite priority review status
The Telix Pharmaceuticals Ltd (ASX: TLX) share price is slipping today, down 2.5% in afternoon trading.
This comes despite the company reporting it had received priority review status from Australia’s Therapeutic Goods Administration (TGA) for its prostate cancer imaging product, TLX591-CDx.
The priority review provides Telix with a fast-tracked timeframe of 150 working days for its product dossier review and approval.
It’s possible this news was already factored into the share price. Telix shares soared 121% higher in the month of November, and the share price is up 152% year-to-date. By comparison, the S&P/ASX 200 Index (ASX: XJO) is flat since 2 January.
What does Telix Pharmaceuticals do?
Telix Pharmaceuticals is a…
-
Noosa News20 hours agoForensic teams, dogs descend on scene of alleged murder
-
General20 hours agoDrone pilot course in doubt as Queensland reviews school-based training
-
Business20 hours agoGuess which $6bn ASX 200 share is being sold off today
-
General8 hours agoCarney cautious after reports of Canada-US trade deal